Publications in collaboration with researchers from Guy's Hospital (2)

2022

  1. Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study

    Clinical Lung Cancer, Vol. 23, Núm. 8, pp. 720-730

2018

  1. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer

    New England Journal of Medicine, Vol. 379, Núm. 21, pp. 2027-2039